

From: Dr. Janice Fitzgerald, Chief Medical Officer of Health

To: Regional Health Authorities, Physicians and Other Primary Care Providers

Re: Update on the Use of Imvamune Vaccine

Date: November 14, 2022

On September 23, 2022, The National Advisory Committee on Immunization (NACI) provided [updated recommendations on the use of Imvamune vaccine](#). NACI now recommends the use of Imvamune vaccine for pre-exposure prophylaxis (PrEP) as well as Post Exposure Prophylaxis (PEP). High-risk individuals eligible to receive PrEP outlined in the updated NACI statement mimic the eligibility criteria already identified by the Department of Health and Community Services (HCS) on August 22, 2022.

Eligibility criteria for the use of Imvamune vaccine continues to include:

- two-spirit people, transgender people, and cisgender males who self-identify as belonging to the gay, bisexual, queer, or men who have sex with men community, and meet at least one of the following criteria, are eligible for preventative vaccination with Imvamune:
 - Have had sex with two or more partners in the last 90 days, or are planning to do so;
 - Have received a diagnosis of a sexually transmitted infection in the last six months;
 - Have attended, worked, or volunteered in venues or other locations for sexual contact within the past 90 days or may be planning to do so, whether in or outside of the province.
- sexual contacts of individuals in the above eligibility groups as well as to people who engage in, or plan to engage in, sex work.



Individuals that meet the criteria above can continue to book immunization appointments for first and second doses through Public Health Offices. Please refer to the following links:

Central Health: [Public Health Offices](#)

Eastern Health: [Health Services – Eastern Health](#)

Labrador Grenfell Health [Contact Us – Labrador-Grenfell Health \(lghealth.ca\)](#)

Western Health [Public Health Offices](#)

Regional Health Authorities should develop communication plans for reaching individuals that received one dose of PrEP as they are now eligible for a second dose.

Individuals who are a close contact to someone with monkeypox will continue to be eligible for post-exposure vaccination. They should contact their local public health office to schedule their vaccination.

The updated NACI statement also offers guidelines on dose sparing techniques in the event of vaccine shortage. HCS does not anticipate vaccine supply issues at this time and will therefore continue to recommend administering Imvamune vaccine through subcutaneous injection. HCS will continue to monitor the supply of Imvamune vaccine and provide updates as needed.

Additional information on Monkeypox is also available at [Monkeypox - Health and Community Services \(gov.nl.ca\)](#)